UCI Discovers New Alzheimer's Gene
News Aug 17, 2009
A UC Irvine study has found that a gene called TOMM40 appears twice as often in people with Alzheimer's disease than in those without it. Alzheimer's, for which there is no cure, is the leading cause of elderly dementia.
Having the harmful form of TOMM40 significantly increases one's susceptibility when other risk factors - such as having a gene called ApoE-4 - are present, the new study reports. People who have ApoE-4 are three to eight times more likely to develop Alzheimer's.
"The TOMM40 gene influences the ease with which molecules can get in and out of mitochondria, the energy production center and stress mediator of cells. TOMM40 also processes materials that form amyloid plaque, a hallmark of Alzheimer's," said Dr. Steven Potkin, lead author of the study and UCI psychiatry & human behavior professor.
"With aging, the number and function of mitochondria decrease, accompanied by a parallel increased risk of developing Alzheimer's," he said. "This study points to the use of mitochondrial-based therapies for treating the disease."
The study will be published Aug. 7 in the journal PLoS One.
Supporting the UCI discovery is research presented recently at the International Conference on Alzheimer's Disease in Austria. Duke University scientists found that patients with TOMM40 developed Alzheimer's an average of seven years earlier than those without the gene.
In addition to Potkin, who is also the Robert R. Sprague Chair in Brain Imaging and director of UCI's Brain Imaging Center, UCI scientists Dr. Fabio Macciardi, Guia Guffanti, Dr. Anita Lakatos, Jessica Turner, Dr. Frithjof Kruggel and James Fallon worked on this study.
They collaborated with Andrew Saykin of Indiana University, Dr. Michael Weiner of UC San Francisco and Alzheimer's Disease Neuroimaging Initiative patients and investigators.
The study was funded by the National Institute of Biomedical Imaging and Bioengineering, the National Institute on Aging, the National Center for Research Resources and an anonymous foundation.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018